Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration

PRECIGEN, INC.

Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.
Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.
Precigen has no further rights or obligations to Castle Creek or retained product royalties.
Proceeds to be used for working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.